Under the deal, Swixx BioPharma will handle the commercialisation activities of oral therapy in 15 CEE markets.
The plasma kallikrein inhibitor Orladeyo has been specifically designed to prevent hereditary angioedema (HAE) attacks in adult and paediatric patients aged 12 years and above.
BioCryst Pharmaceuticals stated that the once-a-day Orladeyo capsule helps prevent HAE attacks by decreasing the plasma kallikrein activity.
The therapy has already received approval in the US and many other markets worldwide.
BioCryst chief commercial officer Charlie Gayer said: “We continue to build partnerships with companies that have deep expertise in commercialising rare disease therapies as we advance our mission of bringing ORLADEYO to patients living with hereditary angioedema around the world.
“The team at Swixx is highly skilled at launching rare disease therapies in Central and Eastern Europe, and we are thrilled to work alongside them to bring our oral, once-daily prophylactic treatment for HAE to patients in this region.”
Back pain, gastroesophageal reflux disease, vomiting, abdominal pain, and diarrhoea are the most common adverse reactions observed in patients receiving Orladeyo.
Swixx BioPharma offers end-to-end services to its partner companies for bringing therapies to treat rare diseases.
Swixx CEO Jean-Michel Lespinasse said: “Based on our unrivalled understanding of the rare disease landscape in CEE, we believe we are best suited to help BioCryst bring Orladeyo to patients living with HAE in the countries within this region.”